makrocare in ppt
TRANSCRIPT
Me An Asset!
Saumitra Rahatekar
+1 (848) 248 9998
02/23/09
Current ScenarioObama administration supporting Stem cell - will translate into more stem cell based therapeutics (Clinical Trials)
Obama Admin is having $300 billion dedicated to EHR for increasing Healthcare efficiency
Advent of Biogenerics will bring in more BA/BE studies
More insurance companies are doing epidemiological studies on life style, effect of diet et.al
Combinatorial Chemistry has increased the number of compounds to be tested
M & A are combining pipelines
Personalized medicine
Current Scenarion (contd.)Sentinel act of monitoring SAEs of drugs in market is new opportunity for Makrocare
Adaptive trials for cutting costs and selecting doses
Global operation for Clinical Research
Abandoning $800 million R & D for a drug and moving to sub $300 million will lead to more outsourcing
Imaging related Clinical Research services will grow @ 40 %
Adv Makrocare
End to end solutions (So less of information transfer issues)
Oracle CDMA, EDC, IVRS and back end IT capability focusing on inter-operability
This will help in doing Adaptive trials
Presence in future mecca of Clinical Research - India , gives us Sun advantage as well allowing to work 24X7
Presence in all major Therapy areas
Global Presence - US, EU, Japan, India
Each day in getting the product in the market delay costs Pharma about $7 million per day, Makrocare is well positioned to reduce this
Business ideas
Its costs nearly 40 cents to manage per $1 worth outsourced services
Bringing down these transaction costs for Pharma companies
Reducing data management costs
To see the world through partner’s eyes and forming joint term goals
New Business model involving partnerships with companies having promising drugs but less finance to take it through, and getting royalties from sales
Introducing micro-dosing for faster human trials thus cutting costs for partner
Focusing on protein therapeutics and nucleotides* - elaborated in forthcoming slides
Business ideas (contd.)
Focusing on Animal Therapeutics market*
Focusing on universities*
Focusing on NGOs*
Keeping tab on John Hopkins, Cleveland Clinic, Mayo Clinic, Mass General Hospital for their best practices and patient outsourcing
Operations flexibility by using Sponsor’s recommended SOPs
Creating online communities for getting feedback on services rendered
Making customer feedback easier for customers
* - elaborated in forthcoming slides
Business ideas (contd.)
Sharing details of # of projects a typical CRA handled simultaneously, with the partner
Integration of Makrocare’s results/reports with clients existing infrastructure for better (real time) decision making on behalf of client
Considering Build-Operate-Transfer model for companies not having presence in India
Making reports smart phone enabled (read - iPhone)
Adopting ‘Freemium’ by doling out free reports thus gaining top of mind recall
Animal Therapeutics & Diagnostics
Important Stats for Animal Therapeutics and Diagnostics
Total market - $22 billion
Growth - 8 % p.a
Total households in US with atleast one pet - 70 million
Top 4 companies - Pfizer, Wyeth, Merial, Intervet
Trends - Vaccination, Animal Obesity and age related diseases
Universities Tech transfer -
University Amount Comments
NYU $650 mln Remicade MAb- J & J
Columbia $135 mln
University of California
$97.6 mln
Northwestern University
$85 mlnPfizer’s Fibromylgia drug
- Lyrica
Wake Forest University
$71.2 mlnMedical device to Kinetic
Concepts
Massachusetts General Hospital
$346 mln
Beckman Research
$118 mln
Emory university
$611 mln Giliead’s HIV - Emtriva
University of Minnesota
$63.3 mln
University of Rochester
$53.3 mln Arthritis drug licensing
NGOs untapped potential
Cystic Fibrosis Foundation pours $76 million in Vertex Pharma for Cystic Fibrosis drug
Leukemia & Lymphoma Society invested $3.7 million in Celator Pharma for funding mid stage clinical trial for drug on Myeloid Leukemia
National Multiple Sclerosis Society paid $1 million for Apitope International NV - Belgian Company
Juvenile Diabetes Research foundation and Osiris Therapeutics - $4 million for Stem cell based Diabetes treatment
Michael J Fox commits $6 million for 3 Parkinson disease clinical trials
RecommendationsNilesh Gupta - President Advanced Market - Lupin Pharma- “Saumitra is an excellent sales person”. (Uses Thomson Pharma and Horizon Global) - This recommendation was after I sold Lupin $ 140,000 product.
Sanjay Bettadpura, - Head Life Science Vertical - Edutech India - “Saumitra brings in an infectious freshness and enthusiasm to the sales and marketing process. Highly creative, and always looking for smarter ways to close deals, he builds great rapport with his customers and genuinely looks to solving their problems rather than just making a sale. Always up-to-date about the industry , his domain knowledge in life sciences is a great plus. As a part of my team, he was always the first to achieve his targets and needed little guidance from me. He is self motivated, takes initiatives and has good problem solving capabilities.His passion for the industry and single mindedness to provide value to customers make a him a great sales and business development person.”
Satheesh Muttathil - Sales training manager - Schering Plough - “Saumitra is enterprising and professional in his approach and is very innovative while executing his commitments. He is highly detail oriented and exhibits excellent planning and organizing skills. His approach is highly customer centric and follows up with customers right through the deal and beyond”
Why meMBA in Biotechnology with 6 years of experience in Life Sciences
Well versed with industry standards - CDISC, 21 CFR Part 11,IVRS, HL-7, GCP, Ethics, eCTD et.al
Doing certified course on SAS Clinical and Oracle Clinical Data Management system
Excellent presentation and communication skills
Good networking capabilities
Uses Web2.0 tools like Linkedin, Twitter for sales leads
Sold Centerwatch services to CROs
Tremendous appetite for knowledge
Understands business - patronize Wall Street Journal and Harvard Business Review
Why me (contd.)
Proactive
Never say die attitude
Out of box thinking
Passionate towards work
Diploma in Supply Chain Management
